Literature DB >> 2611208

Small, but not large, unilamellar liposomes composed of dioleoylphosphatidylethanolamine and oleic acid can be stabilized by human plasma.

D X Liu1, L Huang.   

Abstract

Small unilamellar liposomes, composed of dioleoylphosphatidylethanolamine (DOPE) and oleic acid (OA), prepared by sonication, were incubated in the presence of human plasma at 37 degrees C. The release of entrapped calcein after 8-h incubation was about 15% in plasma, compared with about 70% in phosphate-buffered saline under the same conditions. In contrast, dioleoylphosphatidylcholine (DOPC)/OA liposomes under the same conditions release about 70% in plasma and only 10% in PBS. Total release of calcein from the DOPE/OA liposomes was observed in a PBS solution containing bovine serum albumin, and the release was completely blocked by preincubation of the liposomes with plasma. These results indicate that the unstable DOPE/OA liposomes are stabilized by incubation with plasma. The stabilization process was very fast, being completed within 1 min. Only relatively small liposomes (d less than or equal to 200 nm) were completely stabilized by plasma; larger liposomes were progressively less stabilizable. SDS-polyacrylamide gel electrophoresis of liposomes which had been incubated with plasma and then washed indicated that several proteins were tightly associated with liposomes. Using liposomes containing [14C]OA, it was found that about 70% of the original OA was extracted after 1-h incubation with human plasma at 37 degrees C. Thin-layer chromatographic analysis of the plasma-treated liposomes showed the presence of the plasma lipids in the liposomes. These results suggest that liposomes composed of DOPE/OA are stabilized by protein and/or lipid components from human plasma and that the composition of the liposomes is altered. The mechanism of stabilization is discussed in terms of the surface pressure of small vesicles with a high degree of curvature.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2611208     DOI: 10.1021/bi00445a027

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  Advances in the use of tocols as drug delivery vehicles.

Authors:  Panayiotis P Constantinides; Jihong Han; Stanley S Davis
Journal:  Pharm Res       Date:  2006-01-25       Impact factor: 4.200

Review 2.  Biodegradable nanoparticles for cytosolic delivery of therapeutics.

Authors:  Jaspreet K Vasir; Vinod Labhasetwar
Journal:  Adv Drug Deliv Rev       Date:  2007-06-26       Impact factor: 15.470

Review 3.  Controlling subcellular delivery to optimize therapeutic effect.

Authors:  Mohanad Mossalam; Andrew S Dixon; Carol S Lim
Journal:  Ther Deliv       Date:  2010-07

4.  Electroporation optimization to deliver plasmid DNA into dental follicle cells.

Authors:  Shaomian Yao; Samir Rana; Dawen Liu; Gary E Wise
Journal:  Biotechnol J       Date:  2009-10       Impact factor: 4.677

Review 5.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

6.  Characteristic differences in the lipid composition of middle ear effusions in adult and pediatric patients: phosphatidylethanolamine and phosphatidylserine levels.

Authors:  R Yabe; K Koga; M Iwamori; Y Nagai; Y Numura
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

7.  Thermosensitive sterically stabilized liposomes: formulation and in vitro studies on mechanism of doxorubicin release by bovine serum and human plasma.

Authors:  M H Gaber; K Hong; S K Huang; D Papahadjopoulos
Journal:  Pharm Res       Date:  1995-10       Impact factor: 4.200

8.  Biophysical studies and intracellular destabilization of pH-sensitive liposomes.

Authors:  F Van Bambeke; A Kerkhofs; A Schanck; C Remacle; E Sonveaux; P M Tulkens; M P Mingeot-Leclercq
Journal:  Lipids       Date:  2000-02       Impact factor: 1.646

Review 9.  Innovations in oligonucleotide drug delivery.

Authors:  Melanie A Lysik; Susanna Wu-Pong
Journal:  J Pharm Sci       Date:  2003-08       Impact factor: 3.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.